|Bid||1.7700 x N/A|
|Ask||1.8000 x N/A|
|Day's range||1.6900 - 1.8000|
|52-week range||1.3500 - 6.8400|
|Beta (5Y monthly)||1.42|
|PE ratio (TTM)||N/A|
|Earnings date||29 Nov 2023 - 01 Dec 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||4.66|
TORONTO, November 28, 2023--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today that Phylos Bioscience Inc. ("Phylos"), a U.S. cannabis genetics company and provider of production ready seeds, has achieved the first milestone under the loan agreement entered into in May 2023 (the "Loan Agreement") and has closed the second tranche under the Loan Agreement with Organigram advancing US$2.75 million to Phylos.
Key Takeaways; Cannabis Sector • Organigram received C$124.6 million investment from BAT; the company also announced the appointment of an interim CFO. • Trulieve posts robust Q3 2023 financial results, showcasing strong financial performance, debt reduction, and strategic growth initiatives. • Canopy Growth reported narrowed Q2 losses, indicating a positive shift amid restructuring efforts. • […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared first on Market Exclus
TORONTO, November 10, 2023--The Board of Directors (the "Board") of Organigram Holdings Inc. ("Organigram" or the "Company") (TSX: OGI) (NASDAQ: OGI) today announced that Derrick West has informed Organigram that he will transition away from his role as Chief Financial Officer ("CFO") in order to take time to focus on his health and recovery following surgery later this month.